Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 917-921

  Wickremsinhe, Enaksha R ^a   Tian, Ye ^a   Ruterbories, Kenneth J ^a   Verburg, Elizabeth M ^a   Weerakkody, Govinda J ^a   Kurihara, Atsushi ^b   Farid, Nagy A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENONE DERIVATIVE; BROMOMETHOXYACETOPHENONE; DRUG METABOLITE; PRASUGREL; R 125687; R 125688; R 125689; R 125690; R 138727; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; STEREOCHEMISTRY; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; THIOPHENES;

EID: 34249094271     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.014530     Document Type: Article

References (11)

1. Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, et al. (2007) Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21:169-179.
2. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, and Goldburg MJ (2007) The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos, in press.
3. 12 receptor inhibitor. Thromb Haemost 94:593-598.
4. Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Naganuma H, Li GY, and Winters KJ (2006) The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 47:377-384.
5. Marzo A and Heftman E (2002) Enantioselective analytical methods in pharmacokinetics with specific reference to genetic polymorphic metabolism. J Biochem Biophys Methods 54:57-70.
6. Milliken GA and Johnson DE (1992) Designed experiments, in Analysis of Messy Data, vol 1, Chapman & Hall/CRC, New York.
7. Rehmel JLF, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, and Ring BJ (2006) Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600-607.
8. Reist M, Testa B, Carrupt PA, Jung M, and Schurig V (1995) Racemization, enantiomerization, diastereomerization, and epimerization - their meaning and pharmacological significance. Chirality 7:396-400.
9. Testa B, Carrupt PA, and Gal J (1993) The so-called interconversion of stereoisomeric drugs - an attempt at clarification. Chirality 5:105-111.
10. Tomaszewski J and Rumore MM (1994) Stereoisomeric drugs: FDA's policy statement and the impact on drug development. Drug Dev Ind Pharm 20:119-139.
11. Van Miert ASJPAM (2003) Stereoselectivity in drug development: a clinical perspective? Vet J 165:3-4.